Veritas In Silico Inc.
130A・Growth Market・Pharmaceuticals
Governance
The company has adopted an audit & supervisory board system and introduced an executive officer system from April 2025. As of the date of filing the annual securities report, the Board of Directors consists of 4 members, including 1 outside director (outside ratio 25%), and the Audit & Supervisory Board consists of 3 members, all of whom are outside auditors. A Sustainability Committee has been established, with a framework in place to report and submit important matters to the Board of Directors.
Risk Management
The Company has established the "Risk Management Regulations" and holds meetings of the Risk Management Committee, chaired by the President and Representative Director, in principle once every quarter. Sustainability-related risks are also regularly deliberated and reviewed by this committee, with a framework in place to submit matters to, or report to, the Board of Directors as necessary.
Shareholder Returns
The company continues to pay no dividends for both FY2025 (ending December 2025) and FY2026 (ending December 2025) (forecast), with annual dividends of ¥0.00. No share buybacks or shareholder benefit programs are in place.
Dividend Policy
The annual dividend for FY2025 (ending December 2025) is ¥0.00 (no dividend). The forecast for FY2026 (ending December 2026) is also ¥0.00 (no dividend), unchanged from the prior period. No revision to the dividend policy has been announced.
ESG
The company positions the creation of mRNA-targeted pharmaceuticals as the core of its business strategy for solving social issues, and is engaged in human capital management (target annual paid leave utilization rate: 70% or higher, versus prior-year actual of 83.5%) and climate change response (development of disaster prevention manuals at business sites). It has established a governance structure whereby the director in charge of sustainability proposes initiatives, which are then deliberated and decided upon by the Sustainability Committee.
Last updated: March 23, 2026